Effects of progestogens on the postmenopausal breast

Climacteric

Volumn 5, Issue 3, 2002, Pages 229-235

  De Lignieres B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

17 hydroxysteroid dehydrogenase; Breast cancer; Estradiol; Estrone; Human breast epithelial cells; Postmenoupause; Progesterone; Progestins

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; STEROID;

BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CELL PROLIFERATION; CORRELATION ANALYSIS; CYTOPATHOLOGY; DOSE RESPONSE; ENDOMETRIUM; HORMONE SUBSTITUTION; HUMAN; LUTEAL PHASE; MITOGENESIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SURGICAL STRESS;

EID: 0036387534     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.5.3.229.235     Document Type: Review

References (47)

1. Yancik R, Wesley M, Ries L, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc 2001;285:885-92
2. Rawl SM, Champion VL, Menon U, et al. The impact of age and race on mammography practices. Health Care Women Int 2000;21:583-97
3. Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822
4. Beral B, Banks E, Reeves G, et al. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999;4:191-200
5. Santoro N, Rosenberg Brown J, Adel T, et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-501
6. Hankinson S, Willett W, Manson J, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9
7. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. J Am Med Assoc 2002;287:216-20
8. Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999;130:270-7
9. Gunnarsson C, Olsson BM, Stal O, et al. Abnormal expression of 17β-hydroxysteroid dehydrogenase in breast cancer predicts late recurrence. Cancer Res 2001;61:8448-51
10. Lando JF, Heck KE, Brett KM. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 1999;17:176-80
11. Bush T, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508
12. Santen R, Pinkerton J, McCartney C, et al. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23
13. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485-91
14. Ross R, Paganini-Hill A, Wan P, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32
15. Colditz G, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64
16. Magnusson C, Baron J, Correia N, et al. Breast cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44
17. Willett WC, Colditz G, Stampfer M. Postmenopausal estrogens - opposed, unopposed, or none of the above. J Am Med Assoc 2000;283:534-5
18. American College of Obstetricians and Gynecologists. Risk of breast cancer with estrogen-progestin replacement therapy. Obstet Gynecol 2001;98:1181-3
19. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. J Am Med Assoc 2002;287:734-41
20. Mauvais-Jarvis P. Progesterone and progestins: a general overview. In Bardin W, Milgrom E, Mauvais-Jarvis P, eds. Progesterone and Progestins. New York: Raven Press, 1983:1-16
21. Gompel A, Somaï S, Chaouat M, et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000;65:593-8
22. 1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27 (Kip1) association with cyclin E-Cdk2. J Biol Chem 2001;276:47675-83
23. Malet C, Spritzer P, Guillaumin D, Kuttenn F. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial cells in culture. J Steroid Biochem 2000;73:171-81
24. Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27. Mol Endocrinol 1997;11:1593-607
25. Formby B, Wiley TS. Bcl-2 survivin and variant CD44v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem 1999;202:53-61
26. Ory K, Lebeau J, Levalois C, et al. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat 2001;68:187-98
27. Jordan C, Jeng M, Catherino W, et al. The estrogenic activity of synthetic progestin used in oral contraception. Cancer 1993;71:1501-5
28. Soderqvist G, Von Schoultz B, Tani E, Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol 1993;168:874-9
29. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000;65:659-64
30. Ferguson DJP, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the 'resting' human breast. Br J Cancer 1981;44:177-81
31. Potten CS, Watson RJ, Williams GT, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988;58:163-70
32. Barrat J, De Lignieres B, Marpeau L, et al. Effet in vivo de l'administration locale de progesterone sur l'activité mitotique des galactophores humains. J Gynecol Obstet Biol Reprod 1990;19:269-74
33. Soderqvist G, Isaksson E, Von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-8
34. Miller NA, Thomas M, Martin NJ, et al. Feasibility of obtaining breast epithelial cells from healthy women for studies of cellular proliferation. Breast Cancer Res Treat 1997;43:201-10
35. Hargreaves DF, Knox F, Swindell R, et al. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br J Cancer 1998;78:945-9
36. Hofseth LJ, Raafat AM, Osuchi JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65
37. Chang KJ, Fournier S, Lee TTY, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785-91
38. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9
39. Linares-Cruz G, Fournier S, Simony J, et al. Human breast growth dynamics during menstrual cycle. In Ioannnidou-Mouzaka L, Agnantis NJ, Lopez DM, eds. 22nd Congress of the International Association of Breast Cancer Research. Bologna: Monduzzi, 1998:211-17
40. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41
41. Coulam C, Acacio BD, Hodis HN, et al. Correlation between plasma estradiol and estrone sulfate levels following long-term oral and transdermal administration of estradiol in healthy postmenopausal women. Fertil Steril 1999;72:S182
42. O'Brien SN, Anandjiwala J, Price TM. Differences in the estrogen content of breast adipose tissue in women by menopausal status and hormone use. Obstet Gynecol 1997;90:244-8
43. National Toxicology Program Board of Scientific Counselors. Report on carcinogens background document for steroidal estrogens. US Department of Health and Human Services, 13-14 December 2000:72pp
44. Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res 2000;32:436-9
45. Coldham NG, James VHT. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17β-hydroxysteroid dehydrogenase activity. Int J Cancer 1990;45:174-8
46. Pollow K, Boquoi E, Baumann J, et al. Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast. Mol Cell Endocrinol 1977;6:333-48
47. Fournier S, Kuttenn F, De Cicco F, et al. Estradiol 17β-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endocrinol Metab 1982;55:428-33